2013
From epoxomicin to carfilzomib : chemistry, biology, and medical outcomes
Kim KB, Crews CM. From epoxomicin to carfilzomib : chemistry, biology, and medical outcomes. Natural Product Reports 2013, 30: 600-604. PMID: 23575525, PMCID: PMC3815659, DOI: 10.1039/c3np20126k.Peer-Reviewed Original ResearchConceptsActive natural productsNatural productsNatural product-based drug discoveryAnti-tumor natural productParent lead compoundRational drug designUnprecedented selectivityHigh-throughput screeningPeptide structureMolecular probesImproved activityDrug designLead compoundsDrug discoveryPharmacophoreEpoxyketonesChemistryProductsSelectivityCompoundsTherapeutic agentsBiological processesDiscoveryScaffoldsBristol-Myers Squibb
2008
ChemInform Abstract: Chemical Genetics: Exploring the Role of the Proteasome in Cell Biology Using Natural Products and Other Small Molecule Proteasome Inhibitors
Kim K, Crews C. ChemInform Abstract: Chemical Genetics: Exploring the Role of the Proteasome in Cell Biology Using Natural Products and Other Small Molecule Proteasome Inhibitors. ChemInform 2008, 39: no-no. DOI: 10.1002/chin.200829270.Peer-Reviewed Original Research
2007
Life on the edge: Therapeutic uses of cytotoxic natural products
Crews C, Leuenroth S, Okuhara D, Shotwell J, Markowitz G, Yu Z, Somlo S. Life on the edge: Therapeutic uses of cytotoxic natural products. The FASEB Journal 2007, 21: a38-a38. DOI: 10.1096/fasebj.21.5.a38-b.Peer-Reviewed Original ResearchAutosomal dominant polycystic kidney diseaseCytotoxic concentrationsPhase I clinical trialLei Gong TengDominant polycystic kidney diseasePolycystic kidney diseaseKidney diseaseChinese medicinal herbsClinical trialsMurine modelCyst formationClinical potentialTriptolideTherapeutic usesDrug developmentMedicinal herbsCytotoxic activityCalcium channel polycystin-2Cytostatic signalsPolycystin-2Cytotoxic compoundsNatural products
1999
Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: Insights into specificity and potency
Kim K, Myung J, Sin N, Crews C. Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: Insights into specificity and potency. Bioorganic & Medicinal Chemistry Letters 1999, 9: 3335-3340. PMID: 10612595, DOI: 10.1016/s0960-894x(99)00612-5.Peer-Reviewed Original Research
1998
Eponemycin analogues: syntheses and use as probes of angiogenesis
Sin N, Meng L, Auth H, Crews C. Eponemycin analogues: syntheses and use as probes of angiogenesis. Bioorganic & Medicinal Chemistry 1998, 6: 1209-1217. PMID: 9784862, DOI: 10.1016/s0968-0896(98)00089-3.Peer-Reviewed Original Research
1997
The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2
Sin N, Meng L, Wang M, Wen J, Bornmann W, Crews C. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 6099-6103. PMID: 9177176, PMCID: PMC21008, DOI: 10.1073/pnas.94.12.6099.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAminopeptidasesAnimalsAntibiotics, AntineoplasticBinding SitesCattleCyclohexanesFatty Acids, UnsaturatedHumansKineticsMammalsMetalloendopeptidasesMethionyl AminopeptidasesMolecular Sequence DataNeovascularization, PathologicO-(Chloroacetylcarbamoyl)fumagillolSaccharomyces cerevisiaeSequence AlignmentSequence Homology, Amino AcidSesquiterpenesConceptsMethionine aminopeptidaseMetAP-1MetAP-2Mammalian proteinsBlood vessel formationVegetative growthTNP-470New blood vessel formationPotent biological activitiesMolecular modeProteinFungal metabolitesVessel formationAnimal model studiesAminopeptidaseAnti-angiogenic compoundsDetailed pharmacological studiesBiological activityImportant targetFumagillinClinical trialsSolid tumorsPharmacological studiesNatural productsSaccharomyces